Paloma Partners’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-14,000
| Closed | -$1.85M | – | 189 |
|
|
2024
Q4 | $1.85M | Buy |
14,000
+9,300
| +198% | +$1.31M | 0.08% | 122 |
|
|
2024
Q3 | $684K | Sell |
4,700
-54,400
| -92% | -$7.87M | 0.02% | 525 |
|
|
2024
Q2 | $8.11M | Sell |
59,100
-19,274
| -25% | -$2.57M | 0.23% | 62 |
|
|
2024
Q1 | $10.8M | Buy |
78,374
+62,474
| +393% | +$8.53M | 0.57% | 32 |
|
|
2023
Q4 | $2.16M | Buy |
15,900
+5,100
| +47% | +$622K | 0.08% | 262 |
|
|
2023
Q3 | $1.32M | Sell |
10,800
-3,300
| -23% | -$420K | 0.05% | 315 |
|
|
2023
Q2 | $1.79M | Buy |
14,100
+4,100
| +41% | +$533K | 0.06% | 265 |
|
|
2023
Q1 | $1.29M | Sell |
10,000
-25,200
| -72% | -$3.3M | 0.05% | 321 |
|
|
2022
Q4 | $4.62M | Sell |
35,200
-10,000
| -22% | -$1.29M | 0.21% | 80 |
|
|
2022
Q3 | $5.29M | Buy |
45,200
+13,400
| +42% | +$1.66M | 0.24% | 59 |
|
|
2022
Q2 | $3.74M | Sell |
31,800
-85,000
| -73% | -$10.1M | 0.13% | 142 |
|
|
2022
Q1 | $15.2M | Buy |
116,800
+22,100
| +23% | +$2.88M | 0.45% | 26 |
|
|
2021
Q4 | $14.5M | Buy |
+94,700
| New | +$14.7M | 0.21% | 52 |
|
|
2021
Q3 | – | Sell |
-56,300
| Closed | -$9.21M | – | 1457 |
|
|
2021
Q2 | $9.21M | Buy |
56,300
+45,100
| +403% | +$6.95M | 0.17% | 101 |
|
|
2021
Q1 | $1.69M | Sell |
11,200
-68,100
| -86% | -$10.8M | 0.04% | 475 |
|
|
2020
Q4 | $12M | Buy |
+79,300
| New | +$11.3M | 0.32% | 51 |
|
|
2019
Q4 | – | Sell |
-9,800
| Closed | -$975K | – | 2314 |
|
|
2019
Q3 | $975K | Sell |
9,800
-17,700
| -64% | -$1.85M | 0.02% | 757 |
|
|
2019
Q2 | $3M | Buy |
+27,500
| New | +$2.93M | 0.05% | 290 |
|
|
2019
Q1 | – | Sell |
-9,900
| Closed | -$955K | – | 1793 |
|
|
2018
Q4 | $955K | Sell |
9,900
-5,100
| -34% | -$541K | 0.03% | 474 |
|
|
2018
Q3 | $1.83M | Buy |
+15,000
| New | +$1.77M | 0.03% | 489 |
|
|
2018
Q1 | – | Sell |
-135,000
| Closed | -$14.4M | – | 2082 |
|
|
2017
Q4 | $14.4M | Sell |
135,000
-9,000
| -6% | -$962K | 0.19% | 77 |
|
|
2017
Q3 | $16M | Buy |
144,000
+126,000
| +700% | +$13.5M | 0.22% | 53 |
|
|
2017
Q2 | $1.86M | Sell |
18,000
-221,700
| -92% | -$21.8M | 0.02% | 808 |
|
|
2017
Q1 | $23.4M | Buy |
239,700
+103,800
| +76% | +$9.94M | 0.28% | 48 |
|
|
2016
Q4 | $12M | Sell |
135,900
-45,300
| -25% | -$4.12M | 0.12% | 97 |
|
|
2016
Q3 | $17.5M | Buy |
181,200
+116,100
| +178% | +$11M | 0.22% | 70 |
|
|
2016
Q2 | $5.58M | Buy |
+65,100
| New | +$5.84M | 0.06% | 227 |
|
Other funds holding IBB
MMEA
Paloma Partners's IBB Position: Q1 2025 in Review
Paloma Partners sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 1,680 shares — an estimated $222K sold.
Paloma Partners first reported a position in IBB in Q1 2014 and held it in 31 quarters. The position peaked at $49.6M in Q2 2017. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.
- Paloma Partners reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
- Paloma Partners sold 1,680 iShares Biotechnology ETF shares in Q1 2025, an estimated $222K.
- Paloma Partners first reported a position in iShares Biotechnology ETF in Q1 2014 and held it in 31 quarters.
- Paloma Partners's iShares Biotechnology ETF position peaked at $49.6M in Q2 2017.
- 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.
Based on Paloma Partners's 13F filing for Q1 2025, filed 15 May 2025.